Shares in Bausch & Lomb surged on Monday amid speculation that the North American contact lens and eye care products supplier is exploring a potential sale.
Source: Sharecast
According to the Financial Times, Bausch & Lomb has hired advisers to test the waters with potential buyers as it looks to separate itself from its heavily indebted parent company.
The sale is expected to draw interest from private equity groups, the paper said.
Based on BLCO's market capitalisation on Friday, its enterprise value including debt was around $10bn, though any transaction will likely be at a significant premium.
Bausch Health, which kept an 88% stake in Bausch & Lomb after the latter's stock-market debut two years ago, holds debt of $21bn, half of which is due to mature by the end of 2027.
Bausch & Lomb shares were up 15% at $17.89 by 0937 in New York, while Bausch Health jumped 6% to $6.70.
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
